Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins.
A KulkarniN M Andrews WrightA N ForgetT RamsayR MallickJohanne I WeberpalsPublished in: Cancer medicine (2023)
This real-world data on RMEC suggests there is a role for progestins in select subgroups of women. The PFS for chemotherapy-naïve patients was 17.9 months (14.3, 27.0), versus 6.2 months (3.9, 14.8) following ≥1 line of treatment. The OS was 29.1 months (17.9, 61.1) for chemotherapy-OS was 29.1 months (17.9, 61.1) for chemotherapy-naïve patients versus 23.0 months (10.5, 37.6) for patients previously exposed.
Keyphrases
- endometrial cancer
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- squamous cell carcinoma
- stem cells
- metabolic syndrome
- patient reported outcomes
- radiation therapy
- adipose tissue
- insulin resistance
- skeletal muscle
- pregnant women
- artificial intelligence
- smoking cessation
- big data